ImmunityBio, Inc. (NASDAQ:IBRX) Receives $12.60 Average PT from Analysts

ImmunityBio, Inc. (NASDAQ:IBRX) has been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $12.60.

A number of equities analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Jefferies Financial Group raised their price target on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. BTIG Research boosted their price target on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a report on Monday.

Insider Buying and Selling

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the sale, the director directly owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 501,967 shares of company stock worth $4,466,412 over the last three months. 69.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IBRX. Armistice Capital LLC bought a new stake in ImmunityBio during the 2nd quarter worth $20,497,000. Heights Capital Management Inc. acquired a new stake in shares of ImmunityBio during the third quarter valued at about $16,152,000. Vanguard Group Inc. grew its holdings in shares of ImmunityBio by 26.8% during the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after purchasing an additional 5,837,898 shares during the last quarter. State Street Corp grew its holdings in shares of ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after purchasing an additional 5,139,890 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of ImmunityBio by 439.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock valued at $12,182,000 after buying an additional 5,012,001 shares during the period. 8.58% of the stock is currently owned by institutional investors.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced completion of enrollment in its pivotal randomized Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG‑naïve NMIBC CIS — early completion reduces timeline uncertainty for a potential label‑expanding readout and supports commercial upside for ANKTIVA. Article Title
• Positive Sentiment: Analyst/valuation commentary highlights trial progress and strong ANKTIVA commercial momentum — positive narratives that can support higher forward earnings expectations and investor confidence. Article Title
• Neutral Sentiment: ImmunityBio will host a business update and review FY‑2025 financial results on March 3 — the call could drive volatility depending on revenue, guidance, and clinical updates management provides. Article Title
• Neutral Sentiment: HC Wainwright published a Q1 earnings forecast for ImmunityBio — analyst forecasts and any accompanying model changes will influence near‑term analyst sentiment and target‑price revisions. Article Title
• Negative Sentiment: Director Barry Simon sold 75,000 shares at an average price of $12.01 (disclosed Feb 24) — insider selling can be interpreted by some investors as a signal to reduce exposure, contributing to downward pressure. Article Title
• Negative Sentiment: Reports cite significant intraday profit‑taking (one article notes a ~17% drop after an intraday high) and coverage pointing to a ~7% decline — these articles reflect short‑term selling and headline‑driven volatility that can amplify swings in the stock. Article Title Article Title

ImmunityBio Stock Performance

IBRX stock opened at $9.78 on Wednesday. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $12.43. The company has a market capitalization of $10.05 billion, a PE ratio of -25.74 and a beta of 0.16. The company’s 50-day simple moving average is $5.27 and its 200 day simple moving average is $3.38.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. On average, analysts forecast that ImmunityBio will post -0.92 EPS for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.